期刊
BEST PRACTICE & RESEARCH CLINICAL HAEMATOLOGY
卷 29, 期 3, 页码 308-313出版社
ELSEVIER SCI LTD
DOI: 10.1016/j.beha.2016.10.014
关键词
Tyrosine kinase inhibitors; Chronic myeloid leukaemia; Functional cure
类别
Stopping tyrosine kinase inhibitor (TKI) therapy after achieving a sustained deep molecular response is an emerging treatment goal for patients with chronic myeloid leukaemia in chronic phase (CML-CP). Indeed, the feasibility of stopping TKI therapy has been confirmed in various studies. The Stop Imatinib 1 (STIM1) study has shown a consistent follow-up which allowed defining a new criterion of clinical outcome evaluation, the treatment free remission (TFR). However, announcing a definitive cure remains a challenge owing to the discovery that TKIs spare quiescent leukaemic stem cells (LSC). It is definitely known that even a patient in long-term TFR has persistent LSCs. For this reason, a functional cure has been defined and proposed. (C) 2016 Elsevier Ltd. All rights reserved.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据